



Supplementary Information



Figure S1. ¹H NMR of 4-(2-hydroxyethoxy)benzaldehyde (2).





Figure S2. ¹³C NMR of 4-(2-hydroxyethoxy)benzaldehyde (2).



Figure S3. ¹H NMR of (**3**) (3, 5-dimethyl-1H-pyrrol-2-yl)-(tetramethyl-4, 4-difluoro-4-bora-3a, 4a-diaza-indacene) methyl] phenoxy] ethanol.



Figure S4. ¹³C NMR of (**3**) (3, 5-dimethyl-1H-pyrrol-2-yl)-(tetramethyl-4, 4-difluoro-4-bora-3a, 4a-diaza-indacene) methyl] phenoxy] ethanol.



Figure S5. ¹⁹F NMR of (3) (3, 5-dimethyl-1H-pyrrol-2-yl)-(tetramethyl-4, 4-difluoro-4-bora-3a, 4a-diaza-indacene) methyl] phenoxy] ethanol.



Figure S6. ¹H NMR of (4) tetramethyl-4,4-difluoro-4-bora-3a,4a-diazaindacene)methyl]phenoxy]ethyl (4-nitrophenyl) carbonate.



Figure S7. ¹³C NMR of (4) tetramethyl-4,4-difluoro-4-bora-3a,4a-diazaindacene)methyl]phenoxy]ethyl (4-nitrophenyl) carbonate.



Figure S8. ¹⁹F NMR of (4) tetramethyl-4,4-difluoro-4-bora-3a,4a-diazaindacene)methyl]phenoxy]ethyl (4-nitrophenyl) carbonate.





Figure S9. ¹⁹F NMR of (**4**) tetramethyl-4,4-difluoro-4-bora-3a,4a-diazaindacene)methyl]phenoxy]ethyl (4-nitrophenyl) carbonate.



Figure S10. ¹H NMR of the fluorescent tobramycin derivative (B).



Figure S12. Mass spectrometry data for the fluorescent tobramycin derivative (B).

Elemental Composition Report												
Single Mass Analysis												
Tolerance = 2.0 PPM / DBE: min = -1.5, max = 50.0												
Element prediction: Off												
Number of isotope peaks used for i-FIT = 4												
Monoisotopic Mass, Even Electron Ions												
955 formula(e) evaluated with 2 results within limits (all results (up to 1000) for each mass)												
Elements Used:												
C: 0-80 H	H: 0-120	B: 0-1	N: 4-7	O: 0-12	F: 2-2							
Minimum:					-1.5							
Maximum:			5.0	2.0	50.0							
Mass	Calc. Mass		mDa	PPM	DBE		i-FIT	i-FIT		Formula		
878.4290	878.4283		0.7	0.8	14.5	1.6	C40	H59	В	N7	O12	F2

Figure S13. Elemental composition report for the fluorescent tobramycin derivative (B).



Figure S14. Effect of the molar ratio of AOT:tobramycin on the extraction of tobramycin into dichloromethane.



Figure S15. Tobramycin calibration curve in the absence/presence of AOT.